Other

Kuraray Co., Ltd.

Yamanouchi Pharmaceutical Company Ltd.

Kayaku Antibiotics Research Co., Ltd.

Srl, Inc.

Kayaku Antibiotic Research Co., Ltd.

Ryunosuke Kanamaru

Hiroshi Maeda

Nakao Ishida

Minoru Ueda

Toshihiko Yoshitake

Takao Suzuki

Chikashi Ishioka

A method for detecting nonsense mutations and frameshift mutations in a test nucleic acid fragment which is simple and may be used even when the size of the test nucleic acid fragment is large is disclosed. The method involves inserting the test nucleic acid fragment into a vector containing a promoter, a translational initiation codon, and a reporter gene, and transforming a host cell with the vector to express a fusion polypeptide. The production of the fusion polypeptide is assayed for in the host cell, and non-production of the fusion polypeptide is indicative of a nonsense and/or frameshift mutation in the test nucleic acid fragment.

Method for detecting mutations using an URA3 reporter gene

Substantially pure neocarzinostatin anticancer agents have the formula (A):

Neocarzinostatin derivatives and method of producing the same

Neocarzinostatin derivatives and a process for manufacturing the same

Novel neocarzinostatin anticancer agents have the formula:

Neocarzinostatin complexes, a method for producing the same, and an

Neocarzinostatin derivatives having the formula; ##STR1## wherein N represents a neocarzinostatin residue, and R.sub.1 +R.sub.2 represents a residue of polystyrene-maleic acid copolymer having a molecular weight of 2,500 to 80,000. These neocarzinostatin derivatives are prepared by reacting neocarzinostatin with a polystyrene-maleic acid copolymer containing at least one maleic anhydride residue per molecule. The neocarzinostatin derivatives exhibit anticarcinogenic activity.

Neocarzinostatin derivatives and a process for producing the same

Growing community of inventors

Sendai, Japan

Ryunosuke Kanamaru